Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A central challenge in the opioid crisis in the US has been the underuse of lifesaving treatment and harm reduction programs. Conventional explanations focus on limited access to care when services are not convenient, affordable, or timely. However, these factors exist downstream from other fundamental causes of low utilization. In this article, we focus on the upstream challenges of scaling effective programs to reach more people who would benefit. The opioid crisis spurred numerous inventive approaches such as buprenorphine administered by paramedics and vehicles equipped to dispense methadone. Yet most people with opioid use disorder (OUD) never receive these lifesaving medications. Similarly, harm reduction programs such as syringe services programs and naloxone distribution are vastly underused. Scaling interventions to reduce harm and treat people with OUD will require addressing both technical constraints, such as program complexity, and social barriers, such as opposing community views, to develop effective programs and ensure that they are used by those who need them most.

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2025.00340DOI Listing

Publication Analysis

Top Keywords

opioid crisis
12
harm reduction
12
reduction programs
12
treatment harm
8
programs reach
8
reach people
8
people benefit
8
effective programs
8
programs
6
opioid
4

Similar Publications

Annually, millions of humans and animals suffer from chronic and acute pain, creating welfare and quality of life concerns for both humans and animals who suffer this pain. In developing new therapeutic approaches, the challenge is to accurately measure this pain to ascertain the efficacy of novel therapeutics. Additionally, there is a need to develop new and effective analgesic options that may offer alternatives to using opioids that contribute to the opioid epidemic.

View Article and Find Full Text PDF

The opioid overdose crisis has become a global public health emergency, claiming more than 100,000 lives each year. In North America, shifting opioid prescribing practices in response to the crisis have profoundly affected people living with chronic pain, who now face reduced access to prescription opioids. Against this backdrop, pain stakeholders have become increasingly active in policymaking arenas to shape how opioids and pain are understood.

View Article and Find Full Text PDF

Background: In response to the opioid epidemic, many surgical specialties have adopted nonopioid pain management strategies. Ultrasound (US)-guided peripheral nerve blocks (PNBs) are effective in reducing pain and opioid consumption postsurgery. Liposomal bupivacaine (LB), shown effective in shoulder surgery, was approved in November 2023 for use in US-guided lower extremity blocks.

View Article and Find Full Text PDF

Background: American Indian and Alaska Native (AI/AN) communities experienced a disproportionate increase in opioid-related fatal and non-fatal poisonings during the COVID-19 pandemic. Access to treatment, such as medications for opioid use disorder (MOUD), became even more critical, although research among this population is limited. We completed qualitative interviews with substance use disorder (SUD) treatment providers (i.

View Article and Find Full Text PDF

Background: The opioid crisis continues to claim lives across the United States, which has led to increased attention toward harm reduction strategies as methods for addressing this public health issue. Specifically, naloxone, an opioid overdose reversal drug, became available over-the-counter in 2023, greatly improving its accessibility. However, despite this progress, general awareness about how to use naloxone remains limited, especially among youth who are being increasingly impacted by the opioid epidemic.

View Article and Find Full Text PDF